In the ACTIVE-4A clinical trial, the use of a P2Y12  antagonist in addition to a therapeutic dose of heparin, compared with a therapeutic dose of heparin only, did not improve outcomes of non-critically ill hospitalized COVID-19 patients [84]. Here, P2RY12 is linked to COVID-19.